With an emphasis on Bergenia ligulata's hypoglycaemic, antioxidant, and anti-diabetic qualities, the study investigated the plant's medicinal potential in the treatment of diabetes. Rats were given Streptozotocin (STZ), which is produced by Streptomyces achromogenes, to induce diabetes by damaging β-cells and reducing insulin output. In rats, Bergenia ligulata extract significantly improved insulin levels and glucose tolerance through hypoglycaemic effects. It also protects against the frequent side effects of diabetes, such as protein breakdown and muscular atrophy. The study examined Bergenia ligulata's possible therapeutic uses in the treatment of diabetes, with a focus on the plant's hypoglycaemic, antioxidant, and anti-diabetic properties. To cause diabetes in rats, Streptozotocin (STZ), was administered. This caused damage to β-cells and decreased insulin production. Bergenia ligulata extract produced hypoglycaemic effects that markedly increased insulin levels and glucose tolerance in rats. It also offered a defence against the common consequences of diabetes, such as muscle atrophy and protein breakdown.